Regeneron Surges 2.25% on 67% Volume Spike, Climbs to 186th in Trading Volume Rankings

On September 15, 2025, , , . .

The stock’s performance was driven by renewed investor confidence in its pipeline advancements. Recent updates highlighted progress in preclinical trials for two experimental therapies targeting rare genetic disorders, with preliminary data expected to be presented at an upcoming medical conference. Analysts noted that positive readouts could accelerate regulatory timelines, potentially expanding market access for these candidates.

Meanwhile, strategic partnerships remained a focal point. A newly announced collaboration with a European research institution to co-develop a next-generation monoclonal antibody therapy added momentum to the stock. The partnership leverages Regeneron’s proprietary discovery platform and the institution’s expertise in immunology, with initial funding commitments already secured.

To build an accurate back-test, I need to clarify a few practical details about the trading rule and the universe you have in mind: 1. Market universe • Do you want to screen all U.S. listed stocks, a specific exchange (e.g., NYSE + NASDAQ), or another market? 2. , , or weighted by something else (e.g., ? , or open-to-close? 3. Transaction costs & slippage • Should we include an estimate (e.g., , or assume zero cost? 4. Benchmark (optional) • Would you like the strategy compared to a benchmark (e.g., ? Once I have this information I can set up the data-retrieval plan and run the back-test.